{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 2009
Source:
PRENATAL PLUS by Atlantic Biologicals Corps
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2020)
Source URL:
First approved in 2009
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2009
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
WELLAGE Deep Layer Silky Facial Oil by Hugel Pharma Co.,Ltd.
Source URL:
First approved in 2009
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02645435: Phase 4 Interventional Completed Arthropathy of Hip
(2015)
Source URL:
First approved in 2009
Source:
Prefera OB plus DHA by Alaven Pharmaceutical LLC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Lancell Slimming by MICELLBio Co., Ltd
(2010)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2009
Source:
21 CFR 350
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Dr.eslee Skin Mild by Ajou Medics Co., Ltd
(2018)
Source URL:
First approved in 2009
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Migraine Relief by Rida LLC
(2023)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE